Kirurgisk behandling af type 2-diabetes

Stine Chabert Olesen; Dorte Lindqvist Hansen; Thomas Almdal; Flemming Bendtsen; Inge Nordgaard; Lisbeth Edvardsen Hvolris; Jens J Holst; Lars Naver; Sten Madsbad

Kirurgisk behandling af type 2-diabetes

Stine Chabert Olesen, Dorte Lindqvist Hansen, Thomas Almdal, Flemming Bendtsen, Inge Nordgaard, Lisbeth Edvardsen Hvolris, Jens J Holst, Lars Naver, Sten Madsbad

Abstract

The resolution of diabetes after gastric bypass is already observed during the first days after the operation, while the control of diabetes after gastric banding occurs after weight loss. Other mechanisms than weight loss must therefore explain the improved glucose tolerance. Focus has been on appetite-regulating gut hormone, particularly peptide YY and glucagon-like peptide-1. Nevertheless, other unknown hormones or mechanisms may be involved in the dramatic changes in the glucose metabolism. Development of new drugs and treatments based on the endocrine changes observed after bariatric surgery with the aim of curing type 2-diabetes are warranted.
Udgivelsesdato: 2009-Feb-16

Bidragets oversatte titel	Surgical treatment of diabetes mellitus type 2
Originalsprog	Dansk
Tidsskrift	Ugeskrift for læger
Vol/bind	171
Udgave nummer	8
Sider (fra-til)	615-7
Antal sider	2
ISSN	0041-5782
Status	Udgivet - 2009

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

@article{d83d58a0335511df8ed1000ea68e967b,

title = "Kirurgisk behandling af type 2-diabetes",

abstract = "The resolution of diabetes after gastric bypass is already observed during the first days after the operation, while the control of diabetes after gastric banding occurs after weight loss. Other mechanisms than weight loss must therefore explain the improved glucose tolerance. Focus has been on appetite-regulating gut hormone, particularly peptide YY and glucagon-like peptide-1. Nevertheless, other unknown hormones or mechanisms may be involved in the dramatic changes in the glucose metabolism. Development of new drugs and treatments based on the endocrine changes observed after bariatric surgery with the aim of curing type 2-diabetes are warranted. Udgivelsesdato: 2009-Feb-16",

author = "Olesen, {Stine Chabert} and Hansen, {Dorte Lindqvist} and Thomas Almdal and Flemming Bendtsen and Inge Nordgaard and Hvolris, {Lisbeth Edvardsen} and Holst, {Jens J} and Lars Naver and Sten Madsbad",

note = "Keywords: Anastomosis, Roux-en-Y; Bariatric Surgery; Diabetes Mellitus, Type 2; Gastric Bypass; Gastroplasty; Glucose; Humans; Remission Induction",

year = "2009",

language = "Dansk",

volume = "171",

pages = "615--7",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "8",

}

TY - JOUR

T1 - Kirurgisk behandling af type 2-diabetes

AU - Olesen, Stine Chabert

AU - Hansen, Dorte Lindqvist

AU - Almdal, Thomas

AU - Bendtsen, Flemming

AU - Nordgaard, Inge

AU - Hvolris, Lisbeth Edvardsen

AU - Holst, Jens J

AU - Naver, Lars

AU - Madsbad, Sten

N1 - Keywords: Anastomosis, Roux-en-Y; Bariatric Surgery; Diabetes Mellitus, Type 2; Gastric Bypass; Gastroplasty; Glucose; Humans; Remission Induction

PY - 2009

Y1 - 2009

N2 - The resolution of diabetes after gastric bypass is already observed during the first days after the operation, while the control of diabetes after gastric banding occurs after weight loss. Other mechanisms than weight loss must therefore explain the improved glucose tolerance. Focus has been on appetite-regulating gut hormone, particularly peptide YY and glucagon-like peptide-1. Nevertheless, other unknown hormones or mechanisms may be involved in the dramatic changes in the glucose metabolism. Development of new drugs and treatments based on the endocrine changes observed after bariatric surgery with the aim of curing type 2-diabetes are warranted. Udgivelsesdato: 2009-Feb-16

AB - The resolution of diabetes after gastric bypass is already observed during the first days after the operation, while the control of diabetes after gastric banding occurs after weight loss. Other mechanisms than weight loss must therefore explain the improved glucose tolerance. Focus has been on appetite-regulating gut hormone, particularly peptide YY and glucagon-like peptide-1. Nevertheless, other unknown hormones or mechanisms may be involved in the dramatic changes in the glucose metabolism. Development of new drugs and treatments based on the endocrine changes observed after bariatric surgery with the aim of curing type 2-diabetes are warranted. Udgivelsesdato: 2009-Feb-16

M3 - Tidsskriftartikel

C2 - 19284908

SN - 0041-5782

VL - 171

SP - 615

EP - 617

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 8

ER -